vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Federal Realty Investment Trust (FRT). Click either name above to swap in a different company.
Federal Realty Investment Trust is the larger business by last-quarter revenue ($336.0M vs $196.0M, roughly 1.7× Axsome Therapeutics, Inc.). Federal Realty Investment Trust runs the higher net margin — 38.6% vs -14.6%, a 53.2% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 8.7%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 6.5%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
AXSM vs FRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $336.0M |
| Net Profit | $-28.6M | $129.7M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 53.8% |
| Net Margin | -14.6% | 38.6% |
| Revenue YoY | 65.0% | 8.7% |
| Net Profit YoY | 61.9% | 103.5% |
| EPS (diluted) | $-0.55 | $1.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $336.0M | ||
| Q4 25 | $196.0M | $336.0M | ||
| Q3 25 | $171.0M | $322.3M | ||
| Q2 25 | $150.0M | $311.5M | ||
| Q1 25 | $121.5M | $309.2M | ||
| Q4 24 | $118.8M | $311.4M | ||
| Q3 24 | $104.8M | $303.6M | ||
| Q2 24 | $87.2M | $296.1M |
| Q1 26 | — | $129.7M | ||
| Q4 25 | $-28.6M | $129.7M | ||
| Q3 25 | $-47.2M | $61.6M | ||
| Q2 25 | $-48.0M | $155.9M | ||
| Q1 25 | $-59.4M | $63.8M | ||
| Q4 24 | $-74.9M | $65.5M | ||
| Q3 24 | $-64.6M | $61.0M | ||
| Q2 24 | $-79.3M | $112.0M |
| Q1 26 | — | 53.8% | ||
| Q4 25 | -13.8% | 53.8% | ||
| Q3 25 | -27.0% | 34.3% | ||
| Q2 25 | -24.5% | 65.1% | ||
| Q1 25 | -46.9% | 35.0% | ||
| Q4 24 | -61.1% | 35.1% | ||
| Q3 24 | -59.8% | 34.9% | ||
| Q2 24 | -89.5% | 53.0% |
| Q1 26 | — | 38.6% | ||
| Q4 25 | -14.6% | 38.6% | ||
| Q3 25 | -27.6% | 19.1% | ||
| Q2 25 | -32.0% | 50.0% | ||
| Q1 25 | -48.9% | 20.6% | ||
| Q4 24 | -63.1% | 21.0% | ||
| Q3 24 | -61.7% | 20.1% | ||
| Q2 24 | -91.0% | 37.8% |
| Q1 26 | — | $1.49 | ||
| Q4 25 | $-0.55 | $1.49 | ||
| Q3 25 | $-0.94 | $0.69 | ||
| Q2 25 | $-0.97 | $1.78 | ||
| Q1 25 | $-1.22 | $0.72 | ||
| Q4 24 | $-1.54 | $0.74 | ||
| Q3 24 | $-1.34 | $0.70 | ||
| Q2 24 | $-1.67 | $1.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $107.4M |
| Total DebtLower is stronger | — | $5.0B |
| Stockholders' EquityBook value | $88.3M | $3.2B |
| Total Assets | $689.8M | $9.1B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $107.4M | ||
| Q4 25 | $322.9M | $107.4M | ||
| Q3 25 | $325.3M | $111.3M | ||
| Q2 25 | $303.0M | $177.0M | ||
| Q1 25 | $300.9M | $109.2M | ||
| Q4 24 | $315.4M | $123.4M | ||
| Q3 24 | $327.3M | $97.0M | ||
| Q2 24 | $315.7M | $103.2M |
| Q1 26 | — | $5.0B | ||
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $88.3M | $3.2B | ||
| Q3 25 | $73.7M | $3.2B | ||
| Q2 25 | $73.1M | $3.2B | ||
| Q1 25 | $53.2M | $3.2B | ||
| Q4 24 | $57.0M | $3.2B | ||
| Q3 24 | $92.9M | $3.1B | ||
| Q2 24 | $102.9M | $3.0B |
| Q1 26 | — | $9.1B | ||
| Q4 25 | $689.8M | $9.1B | ||
| Q3 25 | $669.3M | $8.9B | ||
| Q2 25 | $639.8M | $8.6B | ||
| Q1 25 | $596.7M | $8.6B | ||
| Q4 24 | $568.5M | $8.5B | ||
| Q3 24 | $561.5M | $8.5B | ||
| Q2 24 | $548.2M | $8.4B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.42× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $622.4M | ||
| Q3 25 | $1.0M | $147.8M | ||
| Q2 25 | $-32.4M | $150.7M | ||
| Q1 25 | $-43.4M | $179.0M | ||
| Q4 24 | $-26.2M | $574.6M | ||
| Q3 24 | $-18.6M | $144.1M | ||
| Q2 24 | $-30.1M | $169.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.80× | ||
| Q3 25 | — | 2.40× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 2.81× | ||
| Q4 24 | — | 8.77× | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
